$3Bn+ PORTFOLIO VALUE CREATED   .
SEED TO SERIES A . DEEP TECH FOCUS   .
EVERY PITCH GETS A RESPONSE WITHIN 10 DAYS   .
SEED TO SERIES A . DEEP TECH FOCUS   .
$3Bn+ PORTFOLIO VALUE CREATED   .
EVERY PITCH GETS A RESPONSE WITHIN 10 DAYS   .
SEED TO SERIES A . DEEP TECH FOCUS   .
$3Bn+ PORTFOLIO VALUE CREATED   .
SEED TO SERIES A . DEEP TECH FOCUS   .
EVERY PITCH GETS A RESPONSE WITHIN 10 DAYS   .
SEED TO SERIES A . DEEP TECH FOCUS   .
$3Bn+ PORTFOLIO VALUE CREATED   .
EVERY PITCH GETS A RESPONSE WITHIN 10 DAYS   .
SEED TO SERIES A . DEEP TECH FOCUS   .
deep tech | venture capital

How patient capital is quietly reshaping Indian deeptech.

Bhaskar Majumdar
Managing Partner, UIV
August 11, 2026
8 MIN READ

India's deeptech story is usually told through breakthroughs — the chip taped out, the satellite launched, the robot deployed. But the more interesting story is about time: how long these companies take to matter, and who is willing to wait for them.

For most of the last decade, Indian venture capital optimised for speed. Consumer businesses could show traction in quarters, and capital flowed to whatever compounded fastest. Deeptech didn't fit that clock. A semiconductor company might spend three years before its first commercial chip; a spacetech firm longer still. Patience wasn't a virtue — it was a liability on the cap table.

That is changing, and not because deeptech got faster. It's because a cohort of funds decided the timeline was the opportunity, not the obstacle.

The clock problem

Hard technology runs on a different cadence than software. The work is sequential — you cannot parallelise your way through a fabrication run or a launch window. This creates a structural mismatch with a fund model built around five-to-seven-year liquidity. Capital-intensive R&D phases before any revenue signal exists. Regulatory and certification cycles measured in years, not sprints. Talent that is scarce, specialised, and expensive to retain. The funds winning in this space aren't ignoring these constraints. They're underwriting them — pricing the long arc into the thesis from day one.

What patient capital actually does

It's tempting to reduce "patient capital" to simply holding longer. The real difference shows up earlier — in how these investors engage with the slow middle of a company's life, the years between the first cheque and the first proof point.

Underwriting the science, not just the slide

Diligence looks different when the risk is technical rather than commercial. The questions move from can this grow? to can this be built at all, and by this team? That requires investors comfortable sitting with genuine technical uncertainty.

Holding through the dip

Holding through the dip

Every deeptech company has a stretch where the burn is real and the proof isn't there yet. Patient capital is, more than anything, the willingness to stay through that stretch without forcing premature scale.

INVESTOR LOGIN
PARTNER LOGIN
SUBMIT YOUR PITCH